PerpEquities

Gilead Sciences, Inc. (GILD) balance sheet

NASDAQ · Healthcare · Drug Manufacturers - General · 17,000 employees · CEO Daniel O'Day

Price
$170.68 +3.06%
Market cap
$212B
Enterprise value
$231B
Last report
Q3 '26 filed 2026-10-30
Next report
2027-02-09 EPS est. $1.39

At the end of Q3 '26 Gilead Sciences, Inc. (GILD) held $6.44B in cash and short-term investments against $26.2B of debt incl. leases. Total assets $51.4B, total liabilities $38.5B, shareholders' equity $13B.

Balance sheet

Balance sheetTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Assets
Cash & equivalents$6.09B$4.72B$2.77B$5.04B$9.99B$7.93B$5.14B$7.33B$7.56B$7.63B$3.18B$6.44B
Short-term investments$2.27B$1.34B$1.43B$1.66B$1.58B$0$69M$19M$2.05B$15M$0$0
Receivables$4.66B$4.67B$4.66B$4.59B$4.42B$4.39B$4.78B$5.1B$4.91B$4.74B$5.06B$5.01B
Inventory$1.79B$1.85B$2.03B$1.87B$1.71B$1.76B$1.83B$1.79B$1.77B$1.91B$1.95B$1.9B
Other current assets$1.29B$1.46B$1.43B$1.63B$995M$2.83B$2.9B$3.65B$1.14B$4.34B$3.76B$3.21B
Current assets$16.1B$14B$12.3B$14.8B$19.2B$16.9B$14.7B$17.9B$18.3B$18.6B$13.9B$16.6B
Property, plant & equipment (net)$5.32B$5.32B$5.35B$5.39B$5.41B$5.42B$5.46B$5.5B$5.61B$5.64B$5.83B$5.95B
Long-term investments$2.16B$1.14B$710M$730M$0$684M$1.91B$2.01B$2.97B$983M$0$0
Goodwill$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B
Intangible assets$26.5B$23.4B$22.8B$20.5B$19.9B$19.4B$18.6B$18B$17B$16.4B$14B$13.4B
Deferred tax assets$0$0$0$0$2.38B$2.57B$2.72B$2B$1.96B$1.77B$2.49B$2.27B
Other non-current assets$3.8B$4.04B$4.06B$4.76B$3.77B$3.19B$4.03B$4.87B$4.85B$4.55B$4.75B$4.9B
Non-current assets$46B$42.3B$41.3B$39.7B$39.8B$39.5B$41B$40.7B$40.7B$37.6B$35.4B$34.9B
Total assets$62.1B$56.3B$53.6B$54.5B$59B$56.4B$55.7B$58.5B$59B$56.3B$49.4B$51.4B
Liabilities
Accounts payable$550M$622M$537M$903M$833M$737M$582M$808M$715M$645M$674M$934M
Accrued expenses$3.8B$4.26B$3.92B$4.11B$3.89B$4.19B$4.22B$4.93B$4.34B$4.12B$4.23B$4.62B
Short-term debt$1.8B$3.67B$1.81B$1.81B$1.82B$2.81B$2.81B$2.81B$2.81B$1.31B$2.41B$2.42B
Taxes payable$1.21B$1.2B$1.27B$1.54B$1.65B$0$0$0$0$0$0$0
Other current liabilities$3.8B$3.27B$3.25B$3.36B$3.71B$4.62B$3.59B$3.75B$3.86B$3.4B$3.7B$4.03B
Current liabilities$11.3B$13B$10.8B$11.7B$12B$12.3B$11.2B$12.3B$11.8B$9.48B$11B$12B
Long-term debt$23.2B$21.5B$21.5B$21.4B$24.9B$22.1B$22.1B$22.1B$22.1B$20.9B$23.8B$23.8B
Lease obligations (non-current)$546M$0$0$0$498M$0$0$0$0$0$0$0
Deferred tax liabilities$1.59B$933M$907M$794M$724M$709M$652M$597M$402M$392M$333M$318M
Other non-current liabilities$2.77B$3.36B$2.16B$2.18B$1.63B$2.16B$2.15B$2.05B$2.06B$2.12B$2.43B$2.32B
Non-current liabilities$28.1B$25.8B$24.6B$24.4B$27.7B$25B$24.9B$24.8B$24.6B$23.4B$26.6B$26.5B
Total liabilities$39.4B$38.8B$35.4B$36.1B$39.7B$37.4B$36.1B$37.1B$36.4B$32.8B$37.6B$38.5B
Equity
Common stock & paid-in capital$1M$1M$1M$1M$1M$1M$1M$1M$1M$1M$1M$1M
Retained earnings$16.3B$10.7B$11.2B$11.1B$11.5B$10.9B$11.3B$12.8B$13.7B$14.1B$2.2B$3.11B
Accumulated other comprehensive income$28M$69M$93M$73M$132M$92M-$18M$36M$39M$78M$95M$89M
Shareholders' equity$22.8B$17.5B$18.3B$18.5B$19.3B$19.2B$19.7B$21.5B$22.7B$23.5B$11.8B$13B
Debt
Total debt (incl. leases)$25.7B$25.2B$23.4B$23.2B$27.3B$25B$24.9B$24.9B$24.9B$22.2B$26.2B$26.2B
Net debt (debt - cash)$19.6B$20.5B$20.6B$18.2B$17.3B$17B$19.8B$17.6B$17.4B$14.5B$23.1B$19.8B

Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Cash, investments and debt

quarter ends

The other statements

Sources

Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-01